<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338115</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2014.002</org_study_id>
    <nct_id>NCT02338115</nct_id>
  </id_info>
  <brief_title>Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients</brief_title>
  <official_title>Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective observational study is to understand the relationship between&#xD;
      paclitaxel exposure and development of peripheral neuropathy during treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paclitaxel is a chemotherapeutic agent commonly used in various tumor types. Paclitaxel&#xD;
      efficacy and toxicity are &quot;dose-dependent&quot; meaning that increasing the dose increases&#xD;
      treatment efficacy and occurrence of toxicity. When used in the weekly 1-hour infusion&#xD;
      regimen paclitaxel is commonly associated with treatment-limiting sensory peripheral&#xD;
      neuropathy. At the current standard dose of 80 mg/m2 approximately 20-25% of patients&#xD;
      experience treatment-limiting neuropathy.&#xD;
&#xD;
      Drug exposure, not dose, determines treatment efficacy and neuropathy development. When&#xD;
      treated with standard doses there is substantial variability in drug exposure meaning some&#xD;
      patients are receiving less efficacious treatment than optimal. At this time we do not&#xD;
      monitor a patient's exposure because the optimal exposure level has not been defined. The&#xD;
      purpose of this study is to prospectively enroll patients for systematic collection of&#xD;
      exposure and neuropathy data in order to characterize this relationship. Once the&#xD;
      relationship between cumulative exposure and neuropathy has been characterized, this model&#xD;
      will be used to define an exposure target in future prospective exposure-guided&#xD;
      dose-adjustment trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 20, 2016</completion_date>
  <primary_completion_date type="Actual">December 20, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severe neuropathy</measure>
    <time_frame>During 12 cycles of paclitaxel treatment (12 weeks for most patients but longer for patients who have treatment delays. Expected maximum 16 weeks of treatment)</time_frame>
    <description>Increase in sensory scale of PRO measure of 5 points or more</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly paclitaxel treatment group</arm_group_label>
    <description>Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 80mg/m2 weekly x 12 weeks</intervention_name>
    <arm_group_label>Weekly paclitaxel treatment group</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum at end of first infusion and 24 hours after Whole blood prior to infusion, at end of&#xD;
      infusion and 24 hours after, and every 3-4 weeks&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients receiving weekly 1-hour paclitaxel infusions for curative treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of invasive breast cancer&#xD;
&#xD;
          -  Systemic treatment with paclitaxel for curative intent (neoadjuvant, adjuvant, or&#xD;
             oligometastatic disease per PI discretion)&#xD;
&#xD;
          -  80 mg/m2 1-hour infusions weekly for up to 12 weeks&#xD;
&#xD;
          -  Female sex&#xD;
&#xD;
             -&gt;18 years old&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior or concurrent treatment with neurotoxic chemotherapy including any taxane,&#xD;
             vinca alkaloid, platinum, bortezomib, or thalidomide. Note that concurrent biologic&#xD;
             treatment with trastuzumab/pertuzumab for HER2+ patients or prior treatment with&#xD;
             Adriamycin/cyclophosphamide are not reasons for exclusion.&#xD;
&#xD;
          -  Distant metastatic disease&#xD;
&#xD;
          -  Concurrent treatment with duloxetine or enrollment on clinical study of&#xD;
             neuroprotective agent&#xD;
&#xD;
          -  History of allergic reaction to paclitaxel or cremophor EL&#xD;
&#xD;
          -  Current signs or symptoms of severe peripheral neuropathy&#xD;
&#xD;
          -  Known family history of hereditary peripheral neuropathy or Charcot-Marie-Tooth&#xD;
             disease&#xD;
&#xD;
          -  Known current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel L Hertz, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan Rogel Cancer Center</investigator_affiliation>
    <investigator_full_name>Daniel Hertz</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

